Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Blood test vs CT to detect recurrence of colorectal cancer

This week's issue of the Journal of the American Medical Association examines the effect of 3 to 5 Years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer.

News image

Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence.

Professor David Mant and colleagues from the United Kingdom assessed the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent.

The research team performed a randomized clinical trial in 39 National Health Service hospitals in the United Kingdom.

The team recruited 1202 eligible participants between 2003 and 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation.

Participants were randomly assigned to 1 of 4 groups, including 300 patients in the CEA only group, 299 in the CT only group, 302 in the CEA+CT group, and 301 patients in the minimum follow-up group.

Surgical treatment of recurrence with curative intent was 7% in the CEA group
Journal of the American Medical Association

Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years.

CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years.

The team reported that the minimum follow-up group received follow-up if symptoms occurred.

The team's main outcomes included surgical treatment of recurrence with curative intent.

The researcher's secondary outcomes were mortality, time to detection of recurrence, and survival after treatment of recurrence with curative intent.

After a mean 4 years of observation, cancer recurrence was detected in 199 participants overall.

The research team treated 71 of 1202 participants for recurrence with curative intent, with little difference according to Dukes staging.

Surgical treatment of recurrence with curative intent was 2% in the minimum follow-up group, 7% in the CEA group, 8% in the CT group, and 7% in the CEA+CT group.

Compared with minimum follow-up, the absolute difference in the percentage of patients treated with curative intent in the CEA group was 4%, in the CT group was 6%, and in the CEA+CT group was 4%.

The team observed that the number of deaths was not significantly different in the combined intensive monitoring groups vs the minimum follow-up group.

Professor Mant's team concluded, "Among patients who had undergone curative surgery for primary colorectal cancer, intensive imaging or CEA screening each provided an increased rate of surgical treatment of recurrence with curative intent compared with minimal follow-up."

"There was no advantage in combining CEA and CT."

"If there is a survival advantage to any strategy, it is likely to be small."

JAMA 2014; 311(3): 263-270
16 January 2014

Go to top of page Email this page Email this page to a colleague

 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us